Release interim data for IGNYTE anti-PD1 failed melanoma cohort

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced: 4 Nov 2021
Due: 31 Dec 2022
Delivered: by 31 Dec 2022

Deadline
Met
Late
Not met
Today

What the company said

“Interim data in the IGNYTE anti-PD1 failed registration directed melanoma cohort continues to be expected in late 2022”

SourceReplimune Group, Inc. Form 8-K press release, 2021-11-04
FilingSEC filing index
Deadline as statedlate 2022
Deadline used31 Dec 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-REPL-002635
Cite as https://keptindex.org/c/KI-C-2021-REPL-002635/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company confirmed in a February 2023 filing that it provided a data update for the IGNYTE anti-PD1 failed melanoma cohort by the end of 2022.

A
Replimune Group, Inc. 8-K filed 2023-02-09 Regulatory filing · published 9 Feb 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC
“We ended 2022 with a data update from our registration directed IGNYTE cohort of RP1 in anti-PD1 failed melanoma that demonstrated impressive and clinically meaningful activity” ✓ confirmed on the page

Market reaction: the shares moved -11.9% against the S&P 500 over the three sessions around the disclosure (8 Feb 2023 to 13 Feb 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 4 Nov 2021

Deadline 31 Dec 2022 (“late 2022”) · wording expected
Version 2 · stated 10 Jan 2022

Deadline 31 Dec 2022 (“late 2022”) · wording firm

“on track to release interim data in late 2022”
Source for this version
Version 3 · stated 18 May 2023

Deadline 31 Dec 2023 (“Q4 2023”) · wording expected

“the Company expects to announce snapshot data for all patients in Q4 2023”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Commercial launch
Indicative materiality: Medium rules
Action: Release
Deliverable: Interim data for IGNYTE anti-PD1 failed melanoma cohort
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.